AbCellera Biologics Inc (NASDAQ:ABCL) price on Thursday, April 10, fall -4.61% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $2.07.
A look at the stock’s price movement, the close in the last trading session was $2.17, moving within a range at $1.97 and $2.11. The beta value (5-Year monthly) was 0.494. Turning to its 52-week performance, $4.65 and $1.89 were the 52-week high and 52-week low respectively. Overall, ABCL moved -11.91% over the past month.
AbCellera Biologics Inc’s market cap currently stands at around $616.83 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-26.
Turning to the stock’s technical picture we see that short term indicators suggest on average that ABCL is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
9 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 7 recommend ABCL as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ABCL’s current price about -9.55% and -21.59% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 39.88, while 7-day volatility ratio is 11.70% and 7.25% in the 30-day chart. Further, AbCellera Biologics Inc (ABCL) has a beta value of 0.48, and an average true range (ATR) of 0.19. Analysts have given the company’s stock an average 52-week price target of $5, forecast between a low of $5 and high of $5. Looking at the price targets, the low is -141.55% off current price level while to achieve the yearly target high, price needs to move -141.55%. Nonetheless, investors will most likely welcome a -141.55% jump to $5 which is the analysts’ median price.
If we refocus on AbCellera Biologics Inc (NASDAQ:ABCL), historical trading data shows that trading volumes averaged 4.28 over the past 10 days and 4.20 million over the past 3 months. The company’s latest data on shares outstanding shows there are 295.76 million shares.
The 24.97% of AbCellera Biologics Inc’s shares are in the hands of company insiders while institutional holders own 37.05% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 22.79 million on 2025-03-14, giving us a short ratio of 4.6. The data shows that as of 2025-03-14 short interest in AbCellera Biologics Inc (ABCL) stood at 990.0 of shares outstanding, with shares short rising to 20.1 million registered in 2025-02-14. Current price change has pushed the stock -29.35% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ABCL stock continues to rise going into the next quarter.
